Appeals court breathes new life into Teva's Medicare pricing lawsuit
A federal appeals court has partially revived Teva Pharmaceuticals' lawsuit against the Medicare drug price negotiation program. The DC Circuit ruled on Tuesday that Teva's claims can proceed, after a lower court had dismissed the case last fall. The decision comes as Teva faces upcoming price cuts for its drug Austedo under the program.
Related stories
Federal court upholds Medicare drug price negotiation program against Merck's challenge · Healthcare systems
PBMs agree to show TrumpRx pricing · Healthcare systems
Cytokinetics challenges Bristol Myers Squibb's patent in court · Drug development
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “Federal appeals court revives part of Teva's IRA case as Austedo price cuts loom.” Browse more stories.